(1) The governor shall direct the Colorado consortium for prescription drug abuse
prevention to study the barriers to the use of abuse-deterrent opioid analgesic drug
products as a way to reduce abuse and diversion of opioid drug products. On or before January 15, 2017, the consortium shall report its findings to the public
health-care and human services committee and the health, insurance, and environment
committee of the house of representatives and the health and human services committee
of the senate, or their successor committees.
(2) Moneys from the general fund shall not be used for the implementation of this
(3) As used in this section:
(a) “Abuse-deterrent opioid analgesic drug product” means a brand or generic opioid analgesic drug product approved by the United States
food and drug administration with abuse-deterrence labeling claims that indicate that
the drug product is expected to result in a meaningful reduction in abuse.
(b) “Opioid analgesic drug product” means a drug product in the opioid analgesic drug class prescribed to treat moderate
to severe pain or other conditions, whether in immediate release or extended release
or long-acting form, that may be combined with other drug substances to form a single
drug product or dosage form.
FindLaw Codes may not reflect the most recent version of the law in your jurisdiction. Please verify the status of the code you are researching with the state legislature or via Westlaw before relying on it for your legal needs.
Was this helpful?
Response sent, thank you
Welcome to FindLaw's Cases & Codes
A free source of state and federal court opinions, state laws, and the United States Code. For more information about the legal concepts addressed by these cases and statutes, visit FindLaw's Learn About the Law.